Klein Hersh Blog

There is no doubt that we are all living history as we face the COVID-19 pandemic. And while every industry has been impacted by this enormous global challenge, there are some, particularly those surrounding healthcare and technology, that are experiencing record surge due to significant need. Telehealth and virtual care have been brewing in the background for years, but the ...

Drug discovery and manufacturing is rapidly changing across the pharmaceutical industry. The increased focus on rare diseases, along with breakthroughs in biologics, gene and cell therapy, and other forms of personalized medicine, have empowered bold innovation among drug developers. Many companies are leveraging these scientific advancements to pursue a new aspirational focus on finding cures for the most-difficult-to-treat diseases. As ...

Boom in cell and gene therapy Among these segments is cell and gene therapy, where innovative science in areas such as cardiovascular disease, cancer, and genetic disorders is driving rapid R&D activity to address critical unmet patient needs. Recent scientific successes in cell and gene therapy are fostering robust venture investment in start-ups, as well as a flurry of mergers ...

Among the hot topics dominating the buzz at the J.P. Morgan Healthcare Conference earlier this year, high on the list were the profound changes impacting generics and specialty pharma. At the conference, I spoke with executives from companies across each of these industry segments and discussed the unique challenges affecting their business. During these conversations, each executive had one common ...

At the recent HLTH healthcare industry conference in Las Vegas, I had the opportunity to meet with the chief executive officer (CEO) of a prominent venture capital-backed digital health company. As we talked about the hiring needs for her team, she discussed one of the struggles she was having with the recruiting process: “Hiring top executive talent is so critical, ...

Robust capital investment is driving extraordinary growth in the life sciences industry. According to Pitchbook, a researcher covering the venture and private equity markets, $2.8 billion has already been invested in pharma and biotech startups in the first quarter of 2018. This investment level is on track to eclipse the record $10 billion that was invested in 2017. New companies ...

The rising costs of prescription drugs and healthcare delivery is impacting the way the pharmaceutical industry brings new medicines to market. Today, key healthcare stakeholders from the, payer, provider, accountable care organization (ACO), pharmacy benefit manager (PBM), and patient communities are playing an increased role in determining the market access strategies for new drugs.   Concerned with a myriad of ...

The competitive landscape of the life sciences industry is transforming executive recruiting. Growing pressure to rapidly advance scientific discovery and expand market share is making the competition to attract top talent as fierce as ever. Raising the stakes even more for pharma and biotech companies is the current misalignment in the talent market, where demand for the most qualified professionals ...